Bacterial sexually transmitted infections (STIs) have been steadily increasing in gay, bisexual, and other men who have sex with men (MSM) over the past 2 decades. While that trend started prior to the introduction of human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP) in 2012, HIV PrEP has been associated with increases in sexual contacts and decreases in condom use with an resultant acceleration in the increase of bacterial STIs such as gonorrhea, syphilis, and chlamydia.
Individuals aged > 18 years were eligible for participation if they had a diagnosis of untreated gonorrhea and chlamydia. The untreated status was defined as no antibiotic taken in the previous 28 days to treat gonorrhea and chlamydia.
known contraindications or hypersensitivity to doxycycline, pentoxifylline, and nitazoxanide.
Parallel
Doxycyclin
DrugDoxycycline is a moderate-spectrum, second-generation tetracycline that is generally well tolerated
Pentoxifylline
DrugPentoxifylline is a vasoactive agent that improves the flow of blood by reducing its viscosity
Nitazoxanide 500Mg Oral Tablet
DrugNitazoxanide is a broad-spectrum antiparasitic and broad-spectrum antiviral medication that is used in medicine for the treatment of various helminthic, protozoal, and viral infections
treatment of chylamdia in sexually active men
treatment of chylamdia in sexually active men and decreasing resistance to antibiotics
Click on the lead sponsor to view all of their trials.
Tanta University
Lead sponsor
Mostafa Mahmoud Bahaa Clinical Pharmacy Department, Horus University, New Damietta, Egypt
Collaborator
This trial is not recruiting at the moment. You can still explore other options:
